Effects of pre-hospital antiplatelet therapy on the incidence of ards

9Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND: Clinical observations on the potential of pre-hospital antiplatelet therapy in preventing ARDS have been inconsistent. To further the correlation between antiplatelet therapy and ARDS, we conducted a meta-analysis to evaluate the effects of pre-hospital antiplatelet therapy on subjects with ARDS. METHODS: A literature search in major data banks was per-formed. We included prospective and retrospective cohorts, case-control trials, and randomized controlled trials that compared the ARDS incidence in subjects with or without pre-hospital antiplatelet agents. RESULTS: Meta-analysis of 7 studies (a total of 30,291 subjects) showed significantly lower odds of ARDS in the pre-hospital antiplatelet therapy group compared with subjects with no pre-hospital antiplatelet therapy (odds ratio 0.68, 95% CI 0.56–0.83; P < .001). However, ARDS mortalities in the hospital and ICUs were not affected. CONCLUSIONS: These findings indicated that pre-hospital antiplatelet therapy was associated with a reduced rate of ARDS but had no effect on the mortality in the subjects at high risk.

Cite

CITATION STYLE

APA

Jin, W., Chuang, C. C., Jin, H., Ye, J., Kandaswamy, E., Wang, L., & Zuo, L. (2020). Effects of pre-hospital antiplatelet therapy on the incidence of ards. Respiratory Care, 65(7), 1039–1045. https://doi.org/10.4187/respcare.07177

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free